Cancers signal predominantly via either TRAIL-R1 or TRAIL-R2, interestingly though the extent of relative surface expression of the two receptors does not always act as an indicator of the preferred receptor for signalling (MacFarlane et al, 2005; reviewed in Dyer et al, 2007). The gene discussed is TNFRSF10A; the disease is cancer.